Streetbeat News

Analyst Ratings

ADTN

Rosenblatt analyst Mike Genovese has downgraded Adtran (NASDAQ:ADTN) from Buy to Neutral and lowered the price target from $11 to $7.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:25 pm

CHRS

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Coherus BioSciences (NASDAQ:CHRS) but lowers the price target from $20 to $13.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:22 pm

AESI

NOG

VLO

Wall Street's most accurate analysts recommend buying shares of Atlas Energy Solutions Inc. (AESI), Valero Energy Corporation (VLO), and Northern Oil and Gas, Inc. (NOG) due to their high dividend yields. However, all three companies recently reported disappointing earnings.

Portfolio Pulse from Lisa Levin

November 07, 2023 | 1:21 pm

ZNTL

HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Zentalis Pharma (NASDAQ:ZNTL), but has lowered the price target from $55 to $46.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:18 pm

NWE

Ladenburg Thalmann analyst Paul Fremont has downgraded NorthWestern Energy Group (NASDAQ:NWE) from Buy to Neutral and set a price target of $51.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:17 pm

LI

TSLA

Despite strong weekly insurance data from China and rumors of a price hike, Tesla, Inc. (NASDAQ:TSLA) shares traded down in premarket trading on Tuesday. The insurance registrations for Tesla EVs in China were reported at 14,000 units for the week ended Nov. 5. There are also rumors that Tesla China is planning price increases for Model Y SR and LR in the coming weeks. However, the decline in Tesla's stock could be due to the decline in the U.S. stock futures. Separately, Morgan Stanley’s Adam Jonas suggested that Tesla’s stock price might not increase unless the company avoids earnings disappointment, expands EVs beyond the current lineup, and shifts focus to capital-light revenue avenues.

Portfolio Pulse from Shanthi Rexaline

November 07, 2023 | 1:17 pm

VRTX

HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $380 to $390.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:15 pm

OLO

William Blair analyst Bhavan Suri has downgraded Olo (NYSE:OLO) from Outperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:15 pm

AMRC

William Blair analyst Tim Mulrooney has downgraded Ameresco (NYSE:AMRC) from Outperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:13 pm

MRTX

Leerink Partners analyst Andrew Berens has downgraded Mirati Therapeutics (NASDAQ:MRTX) from Outperform to Market Perform and lowered the price target from $78 to $58.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:12 pm